Patrick Wethington

Mr. Wethington is a serial CEO and entrepreneur. He has been involved with a unique list of “market innovation firsts” to tackle some of the leading chronic diseases of our time. Mr. Wethington has had four consecutive M&A exits (Medtronic, St. Jude Medical, Gambro and CryoLife), two as a CEO and two as a global market/commercial lead, and has had a fundraise plus exit value generation track record now approaching over $1 billion (venture, IPO and strategic fundraise-exit). Rounding out this experience, Mr. Wethington has for profit (private and public co.) and not-for-profit independent board member, audit committee chair, oversight committee member, strategic advisor, mentor and leadership experience at medical device, digital healthcare, and academic based organizations. Five years before the Covid-19 pandemic, Mr. Wethington started, co-invented and led the world’s first percutaneous neuromodulation stimulation device company to help wean patients off ventilators ($11.5B total addressable market TAM). Along with other ventures, Mr. Wethington is currently developing and forming a cardiac diagnostic company. Mr. Wethington serves as an Oversight Committee Member on the Technology and Validation Program Committee at Case Western Reserve University, and a mentor for Pre- and Post-Doctoral Biomedical Research Students enrolled in an NIH-funded EB4 program hosted by Washington University. Mr. Wethington currently serves as a strategic advisor for a publicly traded respiratory company.